ClinicalTrials.gg

Program

CLR1404

Also written as “I-131-CLR1404”, “CLR 131” and “Iopofosine I 131”.

Its studies are mostly in Glioma · Waldenstrom Macroglobulinemia · Neoplasms · Neuroblastoma · Multiple Myeloma, led by 2 companies.

Furthest: phase 3, since Jul 30, 20268 company-led studies, 4 open or runningNext primary completion: Jun 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Cellectar Biosciences74 open or runningphase 3since Jul 30, 2026Dec 16, 2011Jun 30, 2027phase 1 · NCT05610891
Cellectar10 open or runningphase 1since Jun 18, 2009Jun 18, 2009none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 18, 2009First study: phase 1 study in RecurrenceNew to CellectarCellectar · NCT00925275 · 9 enrolled · United States
  2. Dec 16, 2011Cellectar Biosciences's first study: phase 1 study in NeoplasmsNew to Cellectar BiosciencesCellectar Biosciences · NCT01495663 · 12 enrolled · United States
  3. Jan 25, 2013Phase 2 study in GliomaCellectar Biosciences · NCT01778088 · United States
  4. Oct 22, 2014Phase 1 study in Multiple MyelomaCellectar Biosciences · NCT02278315 · 31 enrolled · United States
  5. Oct 28, 2016Phase 2 study in Waldenstrom MacroglobulinemiaCellectar Biosciences · NCT02952508 · 120 enrolled · United States, Australia, Brazil and more
  6. Mar 20, 2018Phase 1 study in NeuroblastomaCellectar Biosciences · NCT03478462 · 30 enrolled · United States, Australia, Canada
  7. Oct 28, 2022Phase 1 study in GliomaCellectar Biosciences · NCT05610891 · 50 enrolled · United States, Canada
  8. Jul 30, 2026Phase 3 study in Waldenstrom MacroglobulinemiaPhase 3 reachedCellectar Biosciences · NCT07766421 · 219 planned

Ahead

  1. Jun 30, 2027Primary completion: phase 1 study in GliomaCellectar Biosciences · NCT05610891
  2. Jun 30, 2027Primary completion: phase 1 study in NeuroblastomaCellectar Biosciences · NCT03478462
  3. Jan 2032Primary completion: phase 3 study in Waldenstrom MacroglobulinemiaCellectar Biosciences · NCT07766421

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07766421Waldenstrom Macroglobulinemia3Not yet recruitingCellectar BiosciencesJan 2032219
NCT05610891Glioma · United States, Canada1Active, not recruitingCellectar BiosciencesJun 30, 202750
NCT03478462Neuroblastoma · United States, Australia, Canada1Active, not recruitingCellectar BiosciencesJun 30, 202730
NCT02952508Waldenstrom Macroglobulinemia · United States, Australia, Brazil and more2Active, not recruitingCellectar BiosciencesJun 22, 2026120
NCT02278315Multiple Myeloma · United States1CompletedCellectar BiosciencesDec 9, 202031
NCT01778088Glioma · United States2WithdrawnCellectar BiosciencesJun 20140
NCT01495663Neoplasms · United States1CompletedCellectar BiosciencesNov 201312
NCT00925275Recurrence · United States1CompletedCellectarFeb 20109

How it is read

Names in the registry

  • “I-131-CLR1404”, 4 entries
  • “CLR 131”, 2 entries
  • “Iopofosine I 131”, 1 entry
  • “Iopofosine I 131 fractionated dose”, 1 entry
  • “I-131-CLR1404 Injection”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.